Paula Busse, MD
Allergy & Immunology · New York, NYNPI 1134147937
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by CSL Behring at 55.5% of the total. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $992.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$53K
- Astrazeneca UK Limited$17K
- Fresenius Kabi USA, LLC$7K
- Biocryst Pharmaceuticals, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Novartis Pharma AG$4K
- plus $5K from 4 others
Across 219 payments — averaging $3327.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$198K
- Shire North American Group Inc$194K
- CSL Behring$113K
- Amgen$96K
- Biocryst Pharmaceuticals, Inc.$55K
- Novartis$47K
- plus $27K from 1 others
What the payments were for
- Consulting fees$50,48353%
- Speaking & faculty fees$30,30132%
- Travel & lodging$12,86313%
- Food & beverage$1,6462%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 64 | $52,941 |
| Astrazeneca UK Limited | 10 | $17,113 |
| Fresenius Kabi USA, LLC | 5 | $7,271 |
| Biocryst Pharmaceuticals, Inc. | 6 | $5,241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $4,335 |
| Novartis Pharma AG | 3 | $3,664 |
| Ionis Pharmaceuticals, Inc. | 1 | $2,780 |
| Biocryst US Sales Co., LLC | 1 | $1,375 |
| Regeneron | 1 | $575 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Andembry$9,828
- PH-Icatibant$7,271
- TAKHZYRO$4,335
- Haegarda$4,035
- Orladeyo$3,025
- DONIDALORSEN$2,780
- ENTRESTO$2,167
- LCZ696D_ENTRESTO_CARDIOVASCULAR$1,497
How this compares
$95,309 in reported general payments places this provider in the 90th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 33 | $1,411,889 |
| IcatibantIcatibant Acetate | 17 | $137,314 |
| XolairOmalizumab | 11 | $16,209 |
| Epinephrine | 16 | $2,488 |
| Azelastine Hcl | 26 | $660 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $447 |
| Fluticasone Propionate | 34 | $333 |
| Levocetirizine Dihydrochloride | 20 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $4,335 | $1,411,88933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in New York
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$946K
- Richard InselNew York$269K
- Purvi ParikhNew York$183K
- Arthur LubitzNew York$165K
- Ama AlexisNew York$120K
- Boyan HadjievNew York$97K
- Charlotte Cunningham-RundlesNew York$95K
- Hale YarmohammadiNew York$71K
- Joyce YuNew York$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.